BRAF targeted therapy for patients with melanoma and active brain metastases : a review of clinical effectiveness

BRAF targeted therapy for patients with melanoma and active brain metastases : a review of clinical effectiveness /

Skin cancer is the most common cancer in Canada, with about 6,500 new cases of skin malignant melanoma reported in 2014, and 1250 Canadians expected to die from it in 2017. Approximately 40-60% of melanomas contain a mutation in the gene that encodes BRAF, which leads to constitutive activation of d...

Full description

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK513219/
Full text
Main Authors: Ho, Chuong (Author), Adcock, Lorna (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
Edition:Version 1.0.
Series:Rapid response report (Canadian Agency for Drugs and Technologies in Health)
Subjects:
Melanoma > drug therapy.
Melanoma > secondary.
Antineoplastic Combined Chemotherapy Protocols.
Antineoplastic Agents.
Protein Kinase Inhibitors.
Proto-Oncogene Proteins B-raf > antagonists & inhibitors.
Treatment Outcome.
Canada.
Review.

Internet

http://www.ncbi.nlm.nih.gov/books/NBK513219/
Full text

Similar Items